地黄饮子联合西药治疗帕金森病临床疗效的Meta分析  

Meta-analysis on the Clinical Efficacy of Dihuang Yinzi in the Treatment of Parkinson’s Disease

作　　者：王玉洁 张驰骋 刘钰淇 陈兰兰 田锦勇[3] WANG Yujie;ZHANG Chicheng;LIU Yuqi;CHEN Lanlan;TIAN Jinyong(First Clinical Medical College,Guizhou University of Traditional Chinese Medicine,Guiyang 550002,China;First Clinical Medical College,Zunyi Medical University,Zunyi 563006,China;Department of Neurophysiology,Guizhou Provincial People's Hospital,Guiyang 550002,China)

机构地区：[1]贵州中医药大学第一临床医学院,贵州贵阳550002 [2]遵义医科大学第一临床医学院,贵州遵义563006 [3]贵州省人民医院神经电生理科,贵州贵阳550002

出　　处：《现代中药研究与实践》2025年第1期78-84,共7页Research and Practice on Chinese Medicines

基　　金：贵州省科技计划基金资助项目(黔科合基础[2020]1Z059);贵州省中医药管理局中医药、民族医药科学技术研究课题(QZYY-2021-011)。

摘　　要：目的系统评价地黄饮子联合西药治疗帕金森病的临床疗效。方法检索PubMed、Embase、Web of Science、CNKI、维普、中国生物医学文献数据库(CBM)及万方数据库中关于地黄饮子联合西药治疗帕金森病的随机对照研究(RCT),检索时间从建库至2024年11月,根据纳入排除标准筛选文献,使用Cochrane偏倚风险评估工具进行文献质量评价并提取资料,采用Review Manager 5.4软件进行Meta分析。结果最终纳入12项临床随机对照研究,共916例帕金森病患者。Meta分析结果显示:与对照组比较,治疗组服用地黄饮子能明显提高帕金森病治疗的总有效率[OR=4.40,95%CI(2.86,6.77),P<0.00001];改善统一帕金森病评分量表(UPDRS)评分[MD=-10.26,95%CI(-15.98,-4.54),P=0.0004]、UPDRSⅢ评分[MD=-5.83,95%CI(-7.11,-4.54),P<0.00001]、CSS评分[MD=-4.36,95%CI(-5.31,-3.41),P<0.00001]、PDQ39评分[MD=-6.64,95%CI(-11.16,-2.13),P=0.004]、NMSS评分[MD=-8.02,95%CI(-15.77,-0.27),P<0.00001]、SCOPA-AUT评分[MD=-1.38,95%CI(-1.89,-0.87),P<0.00001]。不良反应率[OR=0.60,95%CI(0.23,1.59),P=0.30]。结论地黄饮子联合西药治疗帕金森病对比单纯西药治疗有更好的临床疗效。Objective To systematically evaluate the efficacy of Dihuang Yinzi combined with western medicine in the treatment of Parkinson’s disease.Methods To search PubMed,Embase,Web of Science,CNKI,VIP,Wanfang database and China Biology Medicine disc(CBM)for randomized controlled trails(RCTs)on the treatment of Parkinson's disease with Dihuang Yinzi,and the searching time was from the establishment of the database to November 2024,and the literature was screened according to the inclusion and exclusion criteria.The Cochrane Risk of Bias Assessment Tool was used to evaluate the quality of literature and extract the information,and Review Manager 5.4 software was used to perform Meta-analysis.Results Finally,12 clinical RCTs and 916 Parkinson’s disease patients were included.Meta-analysis results showed that,compared with the control group,the administration of Dihuang Yinzi in the treatment group significantly increased the overall effective rate of Parkinson’s disease treatment[OR=4.40,95%CI(2.86,6.77),P<0.00001];improved Unified Parkinson’s Disease Rating Scale score[MD=-10.26,95%CI(-15.98,-4.54),P=0.0004],UPDRS III score[MD=-5.83,95%CI(-7.11,-4.54),P<0.00001],CSS score[MD=-4.36,95%CI(-5.31,-3.41),P<0.00001],PDQ39 score[MD=-6.64,95%CI(-11.16,-2.13),P=0.004],NMSS score[MD=-8.02,95%CI(-15.77,-0.27),P<0.00001],SCOPA-AUT score[MD=-1.38,95%CI(-1.89,-0.87),P<0.00001].Adverse reaction rate[OR=0.60,95%CI(0.23,1.59),P=0.30].Conclusion Dihuang Yinzi combined with western medicine has better clinical efficacy in the treatment of Parkinson’s disease than western medicine alone.

关 键 词：地黄饮子 帕金森病 西药 随机对照实验 META分析 

分 类 号：R741[医药卫生—神经病学与精神病学] R287[医药卫生—临床医学]